Moffitt Cancer Center Partners with TuHURA Biopharma Inc. to Develop a New Generation of Targeted Immunotherapies

Moffitt Cancer Center Partners with TuHURA Biopharma Inc. to Develop a New Generation of Targeted Immunotherapies

TAMPA, Fla. and SEATTLE – Moffitt Cancer Center announced today a licensing agreement with TuHURA Biopharma, Inc., a start-up biotechnology company in Seattle, to develop new immunotherapy treatments for cancer that will apply to a greater number of cancers and a larger patient population.

Full Story

Related posts

UCF Researchers Design Custom-Fit 3D-Printed Medical Devices for Infants

UCF researchers detail how they used data from three unidentified pediatric cases from Nemours Children’s…

FSU: Airbnb’s explosive growth jolts hotel industry’s bottom line

New research from Florida State University finds Airbnb’s exponential growth worldwide is devouring an increasing…

FIU: Researchers warn teens about potential harms of vaping

FIU psychologists Elisa Trucco and Matthew Sutherland are educating students, school personnel and parents about…